Page results
-
Information about the Therapeutic Plasma Exchange at NHNN for patients, carers, and families.
-
Holistic Needs Assessment (HNA): Information for people affected by cancer and blood conditions patient information leaflet
-
Christmas is an exciting time even if it will be a bit different for us all this year. We might be spending more time inside, making us less active than usual for this time of year. However, it is still a good time to relax and enjoy some Christmas treats.
-
People with the acquired communication disorder aphasia – which involves problems with the understanding or production of speech –have benefitted greatly from a two-year programme of therapy at the National Hospital for Neurology and Neurosurgery at UCLH.
-
We are pleased to let you know that the NPDA Diabetes at School 2026 PREM is now live!
-
Read more about a UCLH patient saved by special 'before midnight' transfusions.
-
This information will give you an overview of BCG immunotherapy, how it is given and side effects it may cause.
-
Having originally studied classics, and having first worked in publishing and in the British Library, I became a lawyer and spent ten years in commercial litigation practice in the City.
-
Having proton beam therapy under general anaesthetic: information for children aged 1- 4 patient information.
-
The diabetes team have revisited their tips for managing diabetes over the Christmas holidays and updated them for 2022.
File results
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0357 - Multiple myeloma treatments